The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRβ1 chain is associated with the clinical course of multiple sclerosis

Background: Primary progressive multiple sclerosis (PP-MS) differs from relapsing-remitting or secondary progressive MS (RR/SP-MS) in ways suggesting differences in the pathogenic pathways. Susceptibility to both PP-MS and RR/SP-MS is linked to carriage of the HLA molecule DRB1*1501. Several serologically defined HLA-DR groups (DR1, DR4, DR6, and DR9) occur less often in RR/SP-MS than in controls. Some or all of the HLA-DR molecules encoded by alleles in these serologically defined groups have a negatively charged glutamic acid at residue 71 or 74 of the β1 chain (β171/β174). Residues at these positions are important in the formation of pocket 4 in the antigen binding site of the HLA-DR molecule. Objectives: To investigate whether the presence of alleles encoding HLA-DR molecules containing glutamic acid at β171/β174 correlates with the course of MS. Methods: HLA-DR and HLA-DQ alleles and genotypes were analysed in 121 MS patients (50 with PP-MS) and 109 controls by molecular typing. Results: Alleles encoding HLA-DR molecules containing a glutamic acid at β171/β174 occurred less often in patients with RR/SP-MS than in those with PP-MS or controls. In subjects not carrying the DRB1*1501 allele, a much higher proportion of PP-MS patients carried alleles encoding HLA-DR molecules containing a glutamic acid at β171/β174 than did RR/SP-MS patients or controls. Conclusions: The amino acid residues involved in determining the shape and charge of pocket 4 of the HLA-DR β1 chain could influence the clinical course of MS by determining protection against RR/SP-MS or susceptibility to the development of PP-MS.

[1]  J. Hillert,et al.  An immunogenetic heterogeneity in multiple sclerosis , 1991, Journal of Neuroimmunology.

[2]  M. Pender,et al.  Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis , 2003, Journal of Clinical Neuroscience.

[3]  N. Hellings,et al.  Insights into the immunopathogenesis of multiple sclerosis , 2002, Immunologic research.

[4]  Z. Meiner,et al.  HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. , 1999, Archives of neurology.

[5]  J. Hillert,et al.  HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.

[6]  T. Olsson,et al.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[8]  F. Christiansen,et al.  The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases , 1999, Immunological reviews.

[9]  P. Fernlund,et al.  HLA-DQ genotypes in classic type 1 diabetes and in latent autoimmune diabetes of the adult. , 2002, American journal of epidemiology.

[10]  D. Li,et al.  Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions , 2003, Multiple sclerosis.

[11]  R. Vaughan,et al.  HLA-DR and -DQ associations with multiple sclerosis in Turkey. , 1997, Human immunology.

[12]  A. Thompson,et al.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.

[13]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[14]  J. Hillert,et al.  Multiple sclerosis is associated with genes within or close to the HLA‐DR‐DQ subregion on a normal DR15, DQ6, Dw2 haplotype , 1993, Neurology.

[15]  Don C. Wiley,et al.  Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein , 1998, The Journal of experimental medicine.

[16]  H. Weiner,et al.  Extended major histocompatibility complex haplotypes in patients with multiple sclerosis , 1989, Neurology.

[17]  L. Barcellos,et al.  Evidence for the genetic role of human leukocyte antigens in low frequency DRBI*1501 multiple sclerosis patients in Israel , 1999, Multiple sclerosis.

[18]  D. Schaid,et al.  Major histocompatibility complex class II alleles and the course and outcome of MS , 1998, Neurology.

[19]  G. McDonnell,et al.  Major histocompatibility complex class II alleles and the course and outcome of MS. , 1999, Neurology.

[20]  R. Karr,et al.  Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association , 1995, The Journal of experimental medicine.

[21]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[22]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[23]  T. Sasazuki,et al.  A new predictive model for insulin-dependent diabetes mellitus susceptibility based on combinations of molecular HLA-DRB1 and HLA-DQB1 pockets. , 1999, Tissue antigens.

[24]  Don C. Wiley,et al.  Structure of a Complex of the Human α/β T Cell Receptor (TCR) HA1.7, Influenza Hemagglutinin Peptide, and Major Histocompatibility Complex Class II Molecule, HLA-DR4 (DRA0101 and DRB10401) , 2002, The Journal of experimental medicine.

[25]  A. Sette,et al.  Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide , 1995, The Journal of experimental medicine.

[26]  M. Pender,et al.  Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis , 1998, Annals of neurology.

[27]  Robert D. Henderson,et al.  The occurrence of autoimmune diseases in patients with multiple sclerosis and their families , 2000, Journal of Clinical Neuroscience.

[28]  T. Wienker,et al.  Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. , 2000, Human immunology.

[29]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[30]  R. Karr,et al.  Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Harbo,et al.  Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis , 2000, Journal of the Neurological Sciences.

[32]  D. McFarlin,et al.  Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.

[33]  L. Richeldi,et al.  HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. , 1993, Science.

[34]  F. Muntoni,et al.  DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. , 1998, Human molecular genetics.

[35]  R. Papais-Alvarenga,et al.  DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. , 1999, Tissue antigens.

[36]  D. Middleton,et al.  A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis , 1999, Journal of the Neurological Sciences.

[37]  C. Nevinny-Stickel,et al.  Susceptible and protective major histocompatibility complex class II alleles in early-onset pauciarticular juvenile chronic arthritis. , 1994, Human immunology.

[38]  P. Vermersch,et al.  Distortion of the Self-Reactive IgG Antibody Repertoire in Multiple Sclerosis as a New Diagnostic Tool1 , 2004, The Journal of Immunology.

[39]  Junya Chen,et al.  HLA and hypertrophic Hashimoto's thyroiditis in Shanghai Chinese. , 1988, Tissue antigens.

[40]  E. Husebye,et al.  Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. , 2002, The Journal of clinical endocrinology and metabolism.

[41]  U. Wagner,et al.  Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification. , 2002, Rheumatic diseases clinics of North America.

[42]  M. Pender,et al.  Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. , 1997, Brain : a journal of neurology.

[43]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[44]  G. McDonnell,et al.  Primary progressive multiple sclerosis: increasing clarity but many unanswered questions , 2002, Journal of the Neurological Sciences.

[45]  M. Maiers,et al.  The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. , 2001, Tissue antigens.

[46]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[47]  J. Granados,et al.  HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis , 2000, Neurology.

[48]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[49]  J. Ilonen,et al.  Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. , 2002, American journal of medical genetics.

[50]  J. Whitaker,et al.  Clinical and laboratory features of primary progressive and secondary progressive MS , 1999, Neurology.

[51]  G. Stewart,et al.  HLA-DW2, viral immunity and family studies in multiple sclerosis , 1977, Journal of the Neurological Sciences.

[52]  J. Hillert,et al.  HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. , 1991, Tissue antigens.

[53]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.